Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Completion of Patient Enrollment of TREAKISYM® Phase II Trial

Published: Wednesday, March 06, 2013
Last Updated: Wednesday, March 06, 2013
Bookmark and Share
Completion of enrollment in frontline low-grade non-Hodgkin’s lymphoma and mantle cell lymphoma patients.

SymBio Pharmaceuticals Limited has announced the completion of patient enrollment of its Phase II clinical trial of TREAKISYM® (bendamustine hydrochloride, SyB L-0501) in frontline low-grade non-Hodgkin’s lymphoma (NHL) and mantle cell lymphoma (MCL) patients in Japan.

This randomized trial is evaluating the combination of TREAKISYM® and rituximab versus R-CHOP.

SymBio initiated this multicenter open-label Phase II trial as a line extension study for TREAKISYM® in November, 2011, in collaboration with Eisai.

Completion of patient enrollment in this trial has occurred. “Thus far the study has progressed smoothly with no serious adverse events being reported,” said Fuminori Yoshida, President and CEO of SymBio. Trial results with data analysis and evaluation will be finalized as soon as possible.

In partnership with Eisai Co., Ltd. (Eisai), SymBio received marketing approval of TREAKISYM® (SyB L-0501) in October, 2010, for the treatment of patients with relapsed/refractory low-grade NHL and MCL in Japan.

The number of low-grade non-Hodgkin’s lymphoma patients in Japan is estimated to be approximately 11,000, including 4,000 refractory/relapsed patients and 7,000 untreated patients.

Currently, R-CHOP is prescribed as a standard therapy, however, clinical trial results in the U.S. and Europe have shown superiority of the combination of rituximab and bendamustine (R-B) over R-CHOP in terms of safety and efficacy, leading to the inclusion of R-B in the National Comprehensive Cancer Network (NCCN) guidelines, which are used by US physicians in prescribing oncology drugs.

SymBio has also initiated development of TREAKISYM® in refractory/relapsed intermediate and high-grade non-Hodgkin’s lymphoma, and refractory/relapsed multiple myeloma.

The Company also continues to pursue other indications in the hematology setting in order to maximize the potential of this ‘pipeline within a molecule’ and address other unmet medical needs.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

SymBio Initiates Japanese Phase I Trial of Oral Rigosertib (SyB C-1101) in Frontline MDS
U.S. FDA has granted orphan drug designation for the use of rigosertib in MDS.
Thursday, July 25, 2013
SymBio Initiates Japanese Phase II Trial for TREAKISYM®
Company has commenced enrollment for bendamustine in CLL patients.
Friday, May 10, 2013
CTN Accepted for SymBio’s Japan Phase 1 Trial of Rigosertib (SyB L-1101)
U.S. FDA grants orphan drug designation for using rigosertib in MDS and pancreatic cancer.
Thursday, September 27, 2012
SymBio Initiates Japan Phase 2 Trial of Bendamustine HCl (SyB L-0501) in MM
Company has achieved first patient enrollment and start phase 2 clinical trial on December 26.
Tuesday, December 27, 2011
Onconova Presents Phase I Data for Oral Rigosertib at the 53rd ASH Annual Meeting
Oral rigosertib (ON 01910.Na) advancing to Phase II.
Wednesday, December 14, 2011
SymBio Launches TREAKISYM® in Japan
SymBio Pharmaceuticals Limited announces the launch of TREAKISYM® (SyB L-0501, bendamustine hydrochloride) in Japan for the treatment of refractory/relapsed low-grade B-cell non-Hodgkin’s lymphoma and mantle cell lymphoma.
Friday, December 10, 2010
SymBio Completes Patient Enrollment for Mantle Cell Lymphoma in Bendamustine Phase II Clinical Study
The Company intends to collect efficacy and safety data in preparation for NDA filing.
Monday, July 07, 2008
Scientific News
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Chromosomal Chaos
Penn study forms basis for future precision medicine approaches for Sezary syndrome
Enzyme Malfunction May be Why Binge Drinking Can Lead to Alcoholism
A new study in mice shows that restoring the synthesis of a key brain chemical tied to inhibiting addictive behavior may help prevent alcohol cravings following binge drinking.
Key to Natural Detoxifier’s Reactivity Discovered
Results have implications for health, drug design and chemical synthesis.
New Treatment for Obesity Developed
Researchers at the University of Liverpool, working with a global healthcare company, have helped develop a new treatment for obesity.
New Protein Found in Immune Cells
Immunobiologists from the University of Freiburg discover Kidins220/ARMS in B cells and demonstrate its functions.
Will Brain Palpation Soon Be Possible?
Researchers have developed non-invasive brain imaging technique which provides the same information as physical palpation.
Shaking Up the Foundations of Epigenetics
Researchers at the Centre for Genomic Regulation (CRG) and the University of Barcelona (UB) published a study that challenges some of the current beliefs about epigenetics.
Groundbreaking Computer Program Diagnoses Cancer in Two Days
Researchers have combined genetics with computer science and created a new diagnostic technology can with 85 per cent certainty identify the source of the disease and thus target treatment and, ultimately, improve the prognosis for the patient.
Michigan Researchers Use Raman Spectroscopy
inVia confocal Raman microscope used in the study of various childhood diseases.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos